English Polski
Vol 17, No 4 (2020)
Review paper
Published online: 2020-09-08

open access

Page views 8027
Article views/downloads 3627
Get Citation

Connect on Social Media

Connect on Social Media

Coffee: drug, stimulant substance and narcotic

Stanisław Surma1, Monika Romańczyk1, Joanna Fojcik2, Marek Krzystanek3
Psychiatria 2020;17(4):237-246.


Coffee beans has been used for centuries by man. The main ingredient of coffee responsible for the biological effects of its
action is caffeine. When used occasionally or in small quantities may have a beneficial effect on human health and functioning.
Certain beneficial effects of caffeine as a medicine have been proven, especially in neurodegenerative diseases. Caffeine as
a stimulant may improve many aspects of everyday human functioning. However, at higher doses, regularly taken, caffeine
causes tolerance and withdrawal symptoms. Because the use of caffeine is common in the population, it is possible that some
of the population is already addicted to it. The aim of the review is to show cross-sectionally the use of caffeine as a stimulant,
as a substance with potentially medical properties and a substance that may cause addiction, perhaps on a population scale.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Żukiewicz-Sobczak W, Krasowska E, Sobczak P, et al. Wpływ spożycia kawy na orga-nizm człowieka. Med. Og. Nauk Zdr. 2012; 18: 71–76.
  2. Yenisetti SC. Beneficial role of coffee and caffeine in neurodegenerative diseases: a minireview. AIMS Public Health. 2016; 3(2): 407–422.
  3. Jeszka-Skowron M, Zgoła-Grześkowiak A, Grześkowiak T. Analytical methods applied for the characterization and the determination of bioactive compounds in coffee. European Food Research and Technology. 2014; 240(1): 19–31.
  4. Zdrojewicz Z, Grześkowiak K, Łukasiewicz M. Czy picie kawy jest zdrowe? Med Rodz. 2016; 3: 138–145.
  5. Cornelis MC, El-Sohemy A, Cornelis MC, et al. Coffee, caffeine, and coronary heart disease. Curr Opin Lipidol. 2007; 18(1): 13–19.
  6. Salazar-Martinez E, Willett WC, Ascherio A, et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med. 2004; 140(1): 1–8.
  7. O'Keefe JH, DiNicolantonio JJ, Lavie CJ. Coffee for Cardioprotection and Longevity. Prog Cardiovasc Dis. 2018; 61(1): 38–42.
  8. James JE. Critical review of dietary caffeine and blood pressure: a relationship that should be taken more seriously. Psychosom Med. 2004; 66(1): 63–71.
  9. Ashihara H, Sano H, Crozier A. Caffeine and related purine alkaloids: biosynthesis, catabolism, function and genetic engineering. Phytochemistry. 2008; 69(4): 841–856.
  10. Nehlig A, Nehlig A, Debry G. [Effects of coffee and caffeine on fertility, reproduction, lactation, and development. Review of human and animal data]. J Gynecol Obstet Biol Reprod (Paris). 1994; 23(3): 241–256.
  11. Thelle DS, Heyden S, Fodor JG. Coffee and cholesterol in epidemiological and experimental studies. Atherosclerosis. 1987; 67(2-3): 97–103.
  12. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998; 709(1): 27–34.
  13. Resta R, Hooker SW, Laurent AB, et al. Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73). J Clin Invest. 1997; 99(4): 676–683.
  14. Villarreal F, Zimmermann S, Makhsudova L, et al. Modulation of cardiac remodeling by adenosine: In vitro and in vivo effects. Biochemistry of Hypertrophy and Heart Failure. 2003: 17–26.
  15. Ciruela F, Saura C, Canela E, et al. Ligand-Induced Phosphorylation, Clustering, and Desensitization of A1 Adenosine Receptors. Molecular Pharmacology. 1997; 52(5): 788–797.
  16. Ramkumar V, Olah ME, Jacobson KA, et al. Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol. 1991; 40(5): 639–647.
  17. Lazarus M, Shen HY, Cherasse Y, et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci. 2011; 31(27): 10067–10075.
  18. Strain EC, Mumford GK, Silverman K, et al. Caffeine dependence syndrome. Evidence from case histories and experimental evaluations. JAMA. 1994; 272(13): 1043–1048.
  19. Glade MJ. Caffeine-Not just a stimulant. Nutrition. 2010; 26(10): 932–938.
  20. Brunyé TT, Mahoney CR, Rapp DN, et al. Caffeine enhances real-world language processing: evidence from a proofreading task. J Exp Psychol Appl. 2012; 18(1): 95–108.
  21. Ker K, Edwards PJ, Felix LM, et al. Caffeine for the prevention of injuries and errors in shift workers. Cochrane Database Syst Rev. 2010(5): CD008508.
  22. Surma S, Narkiewicz K. Kawa a ryzyko rozwoju nadciśnienia tętniczego i innych chorób układu krążenia. Choroby Serca i Naczyń. 2020; 17(1): 55–64.
  23. Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs. 1995; 49(1): 37–50.
  24. O'Callaghan F, Muurlink O, Reid N. Effects of caffeine on sleep quality and daytime functioning. Risk Manag Healthc Policy. 2018; 11: 263–271.
  25. Kromann CB, Nielsen CT. A case of cola dependency in a woman with recurrent depression. BMC Res Notes. 2012; 5: 692.
  26. Guieu R, Devaux C, Henry H, et al. Adenosine and migraine. Can J Neurol Sci. 1998; 25(1): 55–58.
  27. Brown SG, Waterer GW. Migraine precipitated by adenosine. Med J Aust. 1995; 162(7): 389, 391.
  28. Antonova M, Wienecke T, Olesen J, et al. Prostaglandins in migraine: update. Curr Opin Neurol. 2013; 26(3): 269–275.
  29. Davis RJ, Murdoch CE, Ali M, et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol. 2004; 141(4): 580–585.
  30. Myren M, Olesen J, Gupta S. Prostaglandin E2 receptor expression in the rat trigeminal-vascular system and other brain structures involved in pain. Neurosci Lett. 2012; 506(1): 64–69.
  31. Lipton RB, Diener HC, Robbins MS, et al. Caffeine in the management of patients with headache. J Headache Pain. 2017; 18(1): 107.
  32. Jones HE, Herning RI, Cadet JL, et al. Caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography (EEG) activity. Psychopharmacology (Berl). 2000; 147(4): 371–377.
  33. Couturier EG, Hering R, Steiner TJ. Weekend attacks in migraine patients: caused by caffeine withdrawal? Cephalalgia. 1992; 12(2): 99–100.
  34. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology. 2004; 63(11): 2022–2027.
  35. Ding M, Bhupathiraju SN, Satija A, et al. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation. 2014; 129(6): 643–659.
  36. Larsson SC, Orsini N. Coffee consumption and risk of stroke: a dose-response meta-analysis of prospective studies. Am J Epidemiol. 2011; 174(9): 993–1001.
  37. Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, et al. Coffee consumption and risk of stroke in women. Circulation. 2009; 119(8): 1116–1123.
  38. Kim B, Nam Y, Kim J, et al. Coffee Consumption and Stroke Risk: A Meta-analysis of Epidemiologic Studies. Korean J Fam Med. 2012; 33(6): 356–365.
  39. Liu QP, Wu YF, Cheng HY, et al. Habitual coffee consumption and risk of cognitive decline/dementia: A systematic review and meta-analysis of prospective cohort studies. Nutrition. 2016; 32(6): 628–636.
  40. Larsson SC, Orsini N. Coffee Consumption and Risk of Dementia and Alzheimer's Disease: A Dose-Response Meta-Analysis of Prospective Studies. Nutrients. 2018; 10(10).
  41. Bragança M, Marinho M, Marques J, et al. The influence of espresso coffee on neurocognitive function in HIV-infected patients. AIDS Care. 2016; 28(9): 1149–1153.
  42. Tavani A, La Vecchia C. Coffee, decaffeinated coffee, tea and cancer of the colon and rectum: a review of epidemiological studies, 1990-2003. Cancer Causes Control. 2004; 15(8): 743–757.
  43. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatr Gerontol Int. 2014; 14(2): 430–439.
  44. Ahsan F, Bashir S. Coffee consumption: health perspectives and drawbacks. J Nutr Obes . 2019; 2(1): 101.
  45. Tuomilehto J, Hu G, Bidel S, et al. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA. 2004; 291(10): 1213–1219.
  46. Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep Med Rev. 2017; 31: 70–78.
  47. Takabayashi A, Maruyama K, Tanno Y, et al. The association of coffee consumption and oxygen desaturation index during sleep among Japanese male workers. Sleep Breath. 2019; 23(4): 1027–1031.
  48. Chung KF, Poon YP, Ng TK, et al. Correlates of sleep irregularity in schizophrenia. Psychiatry Research. 2018; 270: 705–714.
  49. Dimitriou D, Le Cornu Knight F, Milton P. The Role of Environmental Factors on Sleep Patterns and School Performance in Adolescents. Front Psychol. 2015; 6: 1717.